Seegene Income Statement

Health Care & Life Sciences » Medical Equipment & Supplies | Seegene Inc.

Seegene Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.

2013

2014

2015

2016

2017

Sales/Revenue

58,993

64,411

65,137

73,694

87,663

Cost of Goods Sold (COGS) incl. D&A

18,222

22,878

24,098

27,401

37,253

Gross Income

40,771

41,533

41,039

46,293

50,410

SG&A Expense

26,681

30,413

32,402

36,209

36,429

EBIT

14,090

11,120

8,637

10,084

13,980

Unusual Expense

198

528

703

209

6,971

Non Operating Income/Expense

310

1,174

1,831

1,064

3,243

Interest Expense

1,344

1,772

1,718

2,185

1,652

Pretax Income

13,020

10,779

8,831

9,867

3,023

Income Tax

2,416

1,653

2,139

2,252

1,027

Equity in Affiliates

1,032

453

Consolidated Net Income

9,573

9,145

6,778

7,161

4,051

Net Income

9,573

9,141

6,774

7,123

3,997

Net Income After Extraordinaries

9,573

9,141

6,774

7,123

3,997

Net Income Available to Common

9,573

9,141

6,774

7,123

3,997

EPS (Basic)

390.67

364.00

264.00

273.00

153.00

Basic Shares Outstanding

EPS (Diluted)

390.10

363.64

263.92

272.96

153.44

Diluted Shares Outstanding

EBITDA

17,323

16,780

14,673

16,639

22,301

Non-Operating Interest Income

783

786

784

1,113

754

Minority Interest Expense

Equity in Affiliates (Pretax)

155

About Seegene

View Profile

Address	Taewon Building Seoul SL 05548 Korea, Republic Of
Employees	-
Website	http://www.seegene.com
Updated	09/14/2018
Seegene, Inc. engages in the development, manufacture, and distribution of molecular diagnostics and reagents. Its IVD Reagents include respiratory pathogen, gastrointestinal pathogen, sexually transmitted infections, human papillomavirus, tuberculosis, sepsis, meningitis, and pathogen. Its instrument types offered are All-in-One, extraction, multiplex PCR, real-time PCR, and auto-electrophoresis.

Seegene Inc. | Income Statement

About Seegene

StatInvestor